CML patients still achieving TFR goals five years after nilotinib An Australian-led trial has confirmed the long term durability and safety of treatment-free remission (TFR) in patients with chronic myeloid leukemia after receiving second-line nilotinib. Latest results from the ENESTop study show that 43% of patients were in TFR at five years. And of the ...
News in brief: CML patients achieve TFR after nilotinib; ISBT In Focus meeting; Bone monitoring urged for HSCT patients
20 May 2021